This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

The company needs Rinvoq and another new immunology drug – recently-approved psoriasis therapy Skyrizi (risankizumab) – to help offset the expected declines in Humira sales once biosimilar ...

That is because Alvotech and commercial partner Teva have claimed approval for their Simlandi biosimilar of Humira ... before the drug is dispensed. Simlandi reaches the market well after its ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

A new clinical review explores the complexities of treating psoriasis during pregnancy and lactation highlighting limited ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...